: + 86-21-6100-2280
Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory condition of the gastrointestinal tract that is usually manifest as 1 of 2 distinct, but sometimes overlapping clinical entities; ulcerative colitis (UC) and Crohn’s disease (CD). While CD is a multifocal, transmural inflammatory process that can affect any part of the digestive tract, UC is characterized by a superficial, continuous inflammation, which is limited to the large intestine. IBD is most commonly diagnosed between the third and fourth decade of life, with no difference noted between males and females.
Until recently, the clinical treatments for UC and CD are relatively limited, essentially comprising of 5-aminosalicylic acid (ASA) compounds, steroids and azathioprine/ 6-mercaptopurine. In the 1990s, immunoregulatory agents used in IBD were expanded to include methotrexate and cyclosporine in select patient populations. The approval of infliximab (Remicade; Centocor), a chimeric monoclonal antibody directed against tumor-necrosis factor-α (TNFα), for the treatment of CD in 1998 by the FDA launched the era of biologic therapy for IBD.
Inflammatory bowel diseases (IBD) are chronic, relapsing inflammatory condition of the gastrointestinal tract, primarily including ulcerative colitis (UC) and Crohn’s disease (CD). DSS induced colitis, closely resembles human UC, is one of the well-established animal models of mucosal inflammation that have been widely used in the study of IBD pathogenesis and preclinical studies. The duration and severity of DSS model are controllable to meet different study needs.
NHP model provides advantage of closer phylogenetic affinity and cross-reactivity to the human specific biological molecules that do not react with rodent counterpart. It emerges as superior evaluation system to help data translation.
Animal: Cynomolgus monkey
Material: : DSS
